Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ) has provided an update.
Wuhan YZY Biopharma Co., Ltd. announced its audited consolidated annual results for the year ending December 31, 2024, revealing a revenue of RMB 107,813,000 and a gross profit of RMB 85,069,000. Despite the positive revenue figures, the company reported a loss before tax of RMB 97,599,000, highlighting ongoing challenges in managing research and development expenses and administrative costs. The financial results indicate a decrease in net assets compared to the previous year, reflecting the company’s strategic investments in R&D and the impact of financial costs on its operations.
More about Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on research and development, offering innovative healthcare solutions and products.
YTD Price Performance: -26.21%
Average Trading Volume: 3,600
Technical Sentiment Signal: Buy
For an in-depth examination of 2496 stock, go to TipRanks’ Stock Analysis page.